Kingsview Wealth Management LLC Decreases Position in AstraZeneca PLC (NASDAQ:AZN)

Kingsview Wealth Management LLC decreased its stake in AstraZeneca PLC (NASDAQ:AZN) by 8.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,954 shares of the company’s stock after selling 1,258 shares during the quarter. Kingsview Wealth Management LLC’s holdings in AstraZeneca were worth $1,009,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of AZN. McClarren Financial Advisors Inc. grew its stake in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter valued at $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the 3rd quarter valued at $28,000. Pathway Financial Advisers LLC purchased a new stake in AstraZeneca in the first quarter worth $29,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $66.36 on Wednesday. The stock has a market capitalization of $205.76 billion, a PE ratio of 31.75, a PEG ratio of 1.20 and a beta of 0.47. The company has a 50 day moving average price of $72.94 and a 200-day moving average price of $77.65. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the business earned $0.87 earnings per share. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. Equities analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.